HEALTH● LOWJul 15 · Jul 15, 2026, 3:35 PM
Roche/ Biogen kidney drug granted FDA priority review for label expansion
Seeking Alpha Tech
A kidney drug developed by Roche and Biogen has been granted priority review by the FDA for an expanded label. This indicates a significant step in the regulatory process for the pharmaceutical product.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH23m agoAfrica Ebola Outbreak Passes 10,000 Cases, Mostly In DR CongoChannels TVHEALTH31m agoNCDC dismisses Ebola rumours, says no confirmed case in NigeriaVanguard NigeriaHEALTH1h agoFG partners US foundation to mobilise $1bn to tackle child malnutritionPremium TimesHEALTH2h agoMarijuana legalization linked to rise in heart-related hospitalizations, study findsThe Hill